5-hydroxytryptamine subtype 6 receptor (5-HT6R) has been extensively considered as a promising therapeutic target for the treatment of neuropathological disorders. 5-HT6R were hypothesized to be implicated in the processes of learning, memory retention, and cognition. Several selective 5-HT6R ligands are currently undergoing clinical trials for treatment of Alzheimer's disease and schizophrenia, SB-742457 and Lu-AE-58054.
MRC researchers at the University of Leicester have shed light on critical gene network involved in neurological disease.
Alzheimer's disease, which currently affects more than 40 million people, is the most common neurodegenerative disease in elder people. Early diagnosis is crucial both to treat the disease and to help the development of new medicines, as it hasn't been possible to find a cure so far.
New research from Sanford Burnham Prebys Medical Discovery Institute (SBP) could help explain why brief bodily stresses -- going to the sauna or for a run, for example -- are good for health and longevity. A study published today in Nature Communications shows that the same cellular process, called autophagy, that's key for extending lifespan is also critical to the benefits of temporary stress.
Salk scientists create synthetic brain systems called 'circuitoids' to better understand dysfunctional movements in Parkinson's, ALS and other diseases.
ÜberResearch and Altmetric, leading data and analytics companies serving scientific funders and research organizations, have published an analysis of Parkinson's disease research papers with the highest Altmetric Attention Scores in the Journal of Parkinson's Disease. The publication is the first in a series aimed at utilizing Altmetric data to provide a more nuanced understanding of how the announcements of new medical discoveries affect the wide-range of disease-specific stakeholders including researchers, funders, care providers, and patients.
Rutgers scientists say neurodegenerative diseases like Alzheimer's and Parkinson's may be linked to defective brain cells disposing toxic proteins that make neighboring cells sick. These findings could have major implications for neurological disease in humans and possibly be the way that disease can spread in the brain.
A team of researchers led by Patrik Verstreken have identified an underlying mechanism in early onset Parkinson's. Using flies, mice and patient cells, the team focused on cardiolipin, a fat unique to cells' mitochondria, organelles that produce energy. They demonstrated that reducing the effects of the protein FASN influences the mitochondria, leading to increased cardiolipin levels and reduced Parkinson's symptoms. These results could pave the way to therapies for Parkinson's disease that target lipids.
In a review of animal studies of Parkinson's disease therapies, Yale researchers identified trends that may contribute to the lack of success in human clinical trials. Their finding provides insight to investigators who seek new therapies to slow the progression of the disease.
Disabling a part of brain cells that acts as a tap to regulate the flow of proteins has been shown to cause neurodegeneration, a new study from The University of Manchester has found.